<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189783</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0780</org_study_id>
    <secondary_id>NCI-2019-07564</secondary_id>
    <secondary_id>2019-0780</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04189783</nct_id>
  </id_info>
  <brief_title>Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients (&quot;RESQU-SARC&quot; Trial)</brief_title>
  <official_title>Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Resection of Retroperitoneal Sarcoma (&quot;RESQU-SARC&quot; Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well a repeat or single liposomal bupivacaine injection
      (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients
      with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second
      injection block may decrease dependency on opioid medications for pain relief after surgery
      and prevent long-term use and addiction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To use a pragmatic phase II randomized controlled trial to compare two standardized
      bundles of usual care for postoperative pain management to reduce the initial discharge
      prescription opioid volume.

      SECONDARY OBJECTIVE:

      I. To assess which pragmatic arm improves aspects of postoperative recovery including 30-day,
      3-month, and 1-year opioid use, patient symptom inventory at those time points, hospital
      measures including length of stay and inpatient pain scores.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive standard of care liposomal bupivacaine injection before and during
      surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence
      of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on
      day 4 after surgery.

      ARM II: Patients receive standard of care liposomal bupivacaine injection before and during
      surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence
      of unacceptable toxicity.

      After completion of study treatment, patients are followed up at 1, 3, and 12 months after
      the surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial discharge prescription oral morphine equivalents (OME)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will perform two-sample t-test to compare the mean doses of discharge prescription OME between the two groups. In addition, multiple linear regression analysis will be carried out to assess the difference between the two arms after adjusting for the stratification factors and other patient characteristics at baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Retroperitoneal Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of disease progression or unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>by injection</description>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
    <other_name>Bupivacaine Liposome Injectable Suspension</other_name>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadratus Lumborum Block</intervention_name>
    <description>by injection</description>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
    <other_name>QL Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective open sarcoma resection for potentially curative intent
             who would otherwise be treated with quadratus lumborum (QL) block +
             intravenous-patient controlled analgesia (IV-PCA) converted to oral pain medications
             (meds) (non-narcotic bundle + opioid pain pill)

        Exclusion Criteria:

          -  Patients with current or past substance (drug or alcohol) abuse disorder

          -  Laparoscopic or minimally invasive surgery

          -  Cases in which anticipated discharge is on or before postoperative day 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Wei D Tzeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ching-Wei D Tzeng</last_name>
    <phone>713-792-6940</phone>
    <email>cdtzeng@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Wei D. Tzeng</last_name>
      <phone>713-792-6940</phone>
    </contact>
    <investigator>
      <last_name>Ching-Wei D. Tzeng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

